Three ways to approach translation
As the general population continues to age, the economic burden of chronic pain and neurodegenerative diseases is increasing and becoming unsustainable. Unfortunately, the pipeline of new therapeutics has thinned over the past several years due to several clinical stage failures. Reasons for these failures may include insufficient understanding of neurobiological mechanisms, poor translation of preclinical data, clinical trial challenges, and the complexity and variability of the human brain and neurological diseases.